GSK Secures Procedural Victory in mRNA Patent Dispute Against Pfizer-BioNTech COVID-19 Vaccine
核心洞察
A U.S. federal judge dismissed Acuitas Therapeutics (搜索)' lawsuit seeking to clear Pfizer-BioNTech's Comirnaty COVID-19 (搜索) vaccine of GSK patent allegations, giving GSK a procedural win in the ongoing mRNA (搜索) technology dispute.
The ruling maintains focus on the main Delaware litigation between GSK and the vaccine makers, where GSK alleges Comirnaty infringes patents for mRNA (搜索) vaccine technology developed over a decade before the pandemic.
GSK previously secured $370 million upfront plus 1% royalties from a separate mRNA (搜索) patent settlement with CureVac and the same vaccine manufacturers in August 2025.
A U.S. federal judge has dismissed Acuitas Therapeutics (搜索) Inc.'s bid to clear Pfizer and BioNTech's Comirnaty COVID-19 (搜索) vaccine of GSK patent allegations, delivering a procedural victory to the British pharmaceutical giant in an ongoing messenger RNA technology dispute that could reshape vaccine royalty landscapes.
Judge Gregory B. Williams granted GSK units' motion to dismiss the case for lack of subject-matter jurisdiction, meaning the court found it lacked power to hear Acuitas' claim in that form. The ruling was issued Thursday in the U.S. District Court for the District of Delaware, with the judge giving parties 21 days to submit a joint proposed redacted version of his sealed concurrent opinion explaining his reasoning.
Strategic Implications for Ongoing Patent Litigation
The ruling matters because it keeps pressure on the main Delaware fight between GSK, Pfizer and BioNTech, rather than letting a supplier-led challenge cut across it. GSK sued the two vaccine makers in 2024, alleging Comirnaty infringed patents tied to mRNA (搜索)-vaccine technology developed more than a decade before the pandemic. Pfizer said then it would defend its position and BioNTech declined to comment.
Acuitas filed its declaratory judgment case on January 2, 2025 against GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC. The complaint sought rulings of non-infringement and invalidity over five GSK patents that sit in GSK's broader case against Pfizer, Pharmacia & Upjohn and BioNTech units over several Comirnaty versions.
Broader mRNA Patent Landscape
The pandemic sales boom has faded, but the patents still matter because they can affect royalties on COVID, flu and combination vaccines as drugmakers push the technology into new uses. Messenger RNA, or mRNA (搜索), uses genetic instructions to prompt an immune response, making it a valuable platform technology across multiple vaccine applications.
The patent fights have spread across the vaccine sector, with GSK pursuing separate pending cases against Moderna over its Spikevax COVID vaccine and mRESVIA RSV shot, according to a vaccine litigation tracker.
Previous Settlement Success
GSK has already drawn cash from a neighboring mRNA (搜索) patent fight. In August 2025, CureVac and GSK settled litigation with Pfizer and BioNTech, with CureVac and GSK receiving $740 million upfront and royalties. GSK's share was $370 million upfront, plus a 1% royalty on U.S. sales by BioNTech and Pfizer of influenza, COVID-19 (搜索) and related combination mRNA vaccine products from the start of 2025. GSK could receive another $130 million and royalties outside the United States if BioNTech's CureVac acquisition closed.
Limited Immediate Impact
However, this is not a ruling on the heart of the dispute. The dismissal does not decide whether Comirnaty infringes GSK's patents, or whether the patents will survive challenges. Pfizer and BioNTech can keep fighting the core case. A dismissal on jurisdiction does not create royalty revenue by itself, and the underlying patent claims may still be narrowed, invalidated or avoided.
Corporate Context
For Chief Executive Luke Miels, the patent cases are useful, but they are not the main investor test. Miels is under pressure to show GSK's research engine can support a target of more than 40 billion pounds in sales by 2031, while the company faces the 2028 patent expiry of dolutegravir, a key HIV (搜索) medicine.
GSK's first-quarter update showed sales of 7.6 billion pounds and core earnings per share of 46.5 pence. The company kept its 2026 turnover growth forecast at 3% to 5%, said it had executed 1.7 billion pounds of a 2 billion pound buyback, and declared a 17 pence first-quarter dividend.
GSK's U.S.-listed shares last traded Friday at $50.41, little changed on the day, with regular London trading closed for the weekend. The muted move suggests the ruling was not enough, on its own, to shift the wider debate over GSK's pipeline, patent cliff and sales target.